139P Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase I study
| Autor: | Starodub, A., Opyrchal, M., Balaraman, R., Barve, M., Fei, D., Li, R., Bai, T., Kong, L., Qin, X., Qin, C., Naqash, A-R. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2023 20 Supplement |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|